Intratympanic steroid injection for ménière's disease
Record ID 32013000579
English
Authors' recommendations:
Ménière's disease (MD) is a chronic, relapsing, intermittent disorder characterized by vertigo, tinnitus (noise in the ear that is only audible to the patient), a sensation of aural pressure, and hearing loss. Episodes may last minutes to hours. The prevalence is 17 to 46 cases in a population of 100,000. MD is difficult to study because of the episodic nature of the symptoms and the tendency in most cases for the episodes of vertigo to eventually cease over a period of many years. MD is characterized by malabsorption of endolymph, the fluid associated with the vestibular canals in the inner ear. There is no cure, and the cause is probably multifactorial: familial, inflammatory, and autoimmune factors may contribute. Initial treatment of MD centers on changes in lifestyle with restriction of salt, caffeine, chocolate, alcohol, and tobacco; control of allergy symptoms; and treatment with betahistine, diuretics, antihistamines, anticholinergics, phenothiazines, or benzodiazepines. Oral corticosteroids are sometimes used for acute attacks. Patients with an inadequate response to conservative therapy may be treated with intratympanic gentamicin or surgery. Medications may be delivered to the middle ear by injection through the tympanic
membrane (eardrum). Liquids deposited in the middle ear can diffuse into the inner ear to reach the auditory and vestibular systems. Intratympanic corticosteroids avoid the undesirable side effects of systemic corticosteroids and may also achieve better inner ear penetration.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=3681
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Meniere Disease
- Glucocorticoids
- Tympanic Membrane
- Injections
- Ear, Middle
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2013 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.